Metabolites

A calcium channel inhibitor.

A calcium channel inhibitor.

Atranorin is a lichen secondary metabolite. Atranorin inhibits lung cancer cell motility and tumorigenesis by affecting AP-1 , Wnt , and STAT signaling and suppressing RhoGTPase activityForm:SolidIC50&amp: Target:RhoGTPase.

Atranorin is a lichen secondary metabolite. Atranorin inhibits lung cancer cell motility and tumorigenesis by affecting AP-1 , Wnt , and STAT signaling and suppressing RhoGTPase activityForm:SolidIC50&amp: Target:RhoGTPase.

Atranorin is a lichen secondary metabolite. Atranorin inhibits lung cancer cell motility and tumorigenesis by affecting AP-1 , Wnt , and STAT signaling and suppressing RhoGTPase activityForm:SolidIC50&amp: Target:RhoGTPase.

Atranorin is a lichen secondary metabolite. Atranorin inhibits lung cancer cell motility and tumorigenesis by affecting AP-1 , Wnt , and STAT signaling and suppressing RhoGTPase activityIC50&amp: Target:RhoGTPase.

AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.

AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.

AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.

AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.

AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.A selective and robust 26S proteasome inhibitor.